Bortezomib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Bortezomib
- Bortezomib: From Plasma Cell Myeloma to Vertebral Anomalies and Variable Endocrine and T-Cell Dysfunction
Bortezomib: From Plasma Cell Myeloma to Vertebral Anomalies and Variable Endocrine and T-Cell Dysfunction
One-Sentence Summary
Bortezomib is a proteasome inhibitor originally used to treat blood cancers: plasma cell myeloma, mantle cell lymphoma, B-cell neoplasm and lymphosarcoma. The TxGNN model predicts it may be effective for vertebral anomalies and variable endocrine and T-cell dysfunction, a rare congenital syndrome. This is a prediction only, with 0 clinical trials and 0 publications currently supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Plasma cell myeloma, mantle cell lymphoma, B-cell neoplasm, lymphosarcoma |
| Predicted New Indication | Vertebral anomalies and variable endocrine and T-cell dysfunction |
| TxGNN Prediction Score | 96.1% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 12 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Bortezomib belongs to the proteasome inhibitor class. Its efficacy in blood cancers is established, and these cancers depend heavily on protein-degradation pathways.
The predicted condition is a rare congenital syndrome combining skeletal, endocrine and T-cell abnormalities. It is not a cancer, and no plausible link between proteasome inhibition and this condition can be drawn from the available data. The high score reflects a pattern in the knowledge graph, not a known biological or clinical connection. Treat it as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Twelve single-ingredient registrations are valid, and none has been cancelled. All are injectable powders for solution (3.5 mg/vial). Approved indication text was not provided for any of them. The five main authorizations are listed below.
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN13064P | Velcade 3.5 mg for Injection (BSP Pharmaceuticals) | Injection, powder, for solution |
| SIN15900P | Pfizer Bortezomib Powder for Injection 3.5 mg (Gland Pharma) | Injection, powder, for solution |
| SIN15594P | Bortesun Powder for Solution for Injection 3.5 mg/vial (Sun Pharmaceutical) | Injection, powder, lyophilized, for solution |
| SIN16732P | Bortezomib-Teva Powder for Solution for Injection 3.5 mg/vial | Injection, powder, lyophilized, for solution |
| SIN16472P | Bortezomib Kabi Powder for Solution for Injection 3.5 mg/vial (Fresenius Kabi Oncology) | Injection, powder, lyophilized, for solution |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (proteasome inhibitor) |
| Myelosuppression Risk | Medium (thrombocytopenia and neutropenia are flagged as concerns in the knowledge graph) |
| Emetogenicity Classification | Low |
| Monitoring Items | CBC with platelets and differential, liver and renal function, peripheral neuropathy assessment |
| Handling Protection | Follow cytotoxic drug handling regulations |
Please also refer to the package insert warnings and precautions.
Safety Considerations
- Contraindication signals (knowledge graph, not label text):
- Blood and liver: thrombocytopenia, neutropenia, agranulocytosis, liver disease, gallbladder disease.
- Nerve and blood pressure: peripheral neuropathy and peripheral nervous system disease, orthostatic hypotension, hypotensive disorder, multiple system atrophy, postural orthostatic tachycardia syndrome.
- Heart and lung: long QT syndrome, cardiovascular and heart disease, pulmonary hypertension, interstitial lung disease, pneumonia, acute respiratory distress syndromes.
- Gut and metabolic: ileus, intestinal obstruction, diabetes mellitus, diabetic ketoacidosis.
- Brain: posterior leukoencephalopathy syndrome.
- Drug Interactions: 100 interactions were found, mostly Moderate.
- Antidiabetic agents are the largest group, including metformin, pioglitazone, acarbose, alogliptin, canagliflozin, dapagliflozin, empagliflozin, exenatide and dulaglutide. Glucose monitoring is advisable.
- Other moderate interactions include aprepitant, clarithromycin, metronidazole, clotrimazole and ascorbic acid.
- Dexamethasone and esomeprazole are Minor.
Label-based warnings and contraindications were not available. Please refer to the package insert for the authoritative safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no trials, no literature and no plausible mechanism for this rare congenital syndrome. A cytotoxic-class drug with notable haematological and neurological risks is hard to justify for a non-cancer syndrome without supporting evidence.
Other predicted indications for bortezomib in the same dataset have stronger support and merit prioritisation instead:
- Neuroblastoma: three completed Phase 1 or 1/2 trials plus extensive preclinical data.
- Hodgkin lymphoma: Phase 2 trials.
- Myeloid leukaemia: Phase 2 trials.
To proceed, the following is needed:
- Detailed mechanism of action data and a biological rationale linking proteasome inhibition to this syndrome
- Any preclinical or case-level evidence in this condition
- Package insert warnings and contraindications from the HSA
- A risk-benefit assessment for a non-oncology, likely paediatric population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.